Mary Dibiase Sells 15,409 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFORGet Free Report) COO Mary Dibiase sold 15,409 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $13,559.92. Following the completion of the sale, the chief operating officer now owns 291,752 shares in the company, valued at approximately $256,741.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mary Dibiase also recently made the following trade(s):

  • On Monday, February 12th, Mary Dibiase sold 3,683 shares of X4 Pharmaceuticals stock. The stock was sold at an average price of $1.01, for a total value of $3,719.83.

X4 Pharmaceuticals Stock Performance

X4 Pharmaceuticals stock traded up $0.03 during mid-day trading on Monday, hitting $0.91. The company had a trading volume of 1,795,123 shares, compared to its average volume of 1,325,463. The company has a current ratio of 5.81, a quick ratio of 5.81 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $152.70 million, a price-to-earnings ratio of -1.16 and a beta of 0.44. The company’s fifty day moving average is $0.87 and its 200-day moving average is $0.90. X4 Pharmaceuticals, Inc. has a 12-month low of $0.57 and a 12-month high of $2.58.

Analyst Upgrades and Downgrades

Separately, B. Riley lowered X4 Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $3.00 to $1.00 in a research report on Tuesday, December 12th.

View Our Latest Stock Analysis on X4 Pharmaceuticals

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Bain Capital Life Sciences Investors LLC raised its stake in shares of X4 Pharmaceuticals by 6.0% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock worth $14,184,000 after buying an additional 955,196 shares during the period. BlackRock Inc. raised its stake in shares of X4 Pharmaceuticals by 2,547.2% during the 2nd quarter. BlackRock Inc. now owns 9,095,274 shares of the company’s stock worth $17,645,000 after buying an additional 8,751,694 shares during the period. Vanguard Group Inc. raised its stake in shares of X4 Pharmaceuticals by 2.4% during the 4th quarter. Vanguard Group Inc. now owns 8,008,865 shares of the company’s stock worth $6,715,000 after buying an additional 184,148 shares during the period. Stonepine Capital Management LLC raised its stake in shares of X4 Pharmaceuticals by 14.5% during the 3rd quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock worth $5,748,000 after buying an additional 668,422 shares during the period. Finally, Polar Capital Holdings Plc acquired a new position in shares of X4 Pharmaceuticals during the 2nd quarter worth approximately $9,700,000. 78.50% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

(Get Free Report)

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.

Read More

Insider Buying and Selling by Quarter for X4 Pharmaceuticals (NASDAQ:XFOR)

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.